Preclinical studies have found that targeting the immunological checkpoint complex CD47-SIRPα can inhibit the development of glioblastoma, enhance the function of phagocytic cells, restore the function of dendritic cells and T lymphocytes, and exert anti-tumor effects by improving innate and adaptive immune responses. Here, CD47 is linked to neoplasm.